Trial Profile
A non-inferiority trial about the efficacy, safety, and effect on QOL of weekly-DPP-4 inhibitor omarigliptin by the comparison with once-daily-DPP-4 inhibitor linagliptin in maintenance hemodialysis patients with type 2 diabetes.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Jul 2019
Price :
$35
*
At a glance
- Drugs Omarigliptin (Primary) ; Linagliptin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 11 Jun 2019 Primary endpoint (Changes in glycoalbumin (GA) and HbA1c over 24 weeks from baseline) has been met as per results presented at the 79th Annual Scientific Sessions of the American Diabetes Association
- 11 Jun 2019 Results presented at the 79th Annual Scientific Sessions of the American Diabetes Association
- 30 Mar 2019 Status changed from active, no longer recruiting to completed.